A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.8576
Abstract: 8576 Background: Thymic epithelial tumors (TETs) are rare but the most common tumor of the anterior mediastinum. Platinum-based combination chemotherapy is standard of care which is associated with a 50%-90% overall response rate (ORR) in… read more here.
Keywords: chemotherapy; thymic epithelial; recurrent refractory; study palbociclib ... See more keywords